Trial
NCT05103826
A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
ER+ / HER2- Advanced Breast Cancer
Intervention
SHR6390、Famitinib
Why stopped
Sponsor R \& D Strategy Adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-15